Vyndaqel Market Outlook 2026-2034: by Disease Type (Transthyretin-Mediated Amyloidosis Cardiomyopathy, Transthyretin-Mediated Amyloidosis Polyneuropathy), Payer Type, Patient Setting, Distribution Channel

The Vyndaqel Market is estimated at US$9.7 billion in 2026 and is projected to grow at a CAGR of 13.8% to reach US$27.3 billion by 2034.

Market Overview

The Vyndaqel Market covers specialty treatment channels and patient care pathways centered on tafamidis use for transthyretin amyloid cardiomyopathy and related specialist cardiac management.

Its value chain includes biopharmaceutical manufacturers, specialty distributors, cardiology centers, hospitals, specialty pharmacies, diagnostic partners, and payer support programs. Core applications include amyloid cardiomyopathy treatment, specialist cardiology care, hospital prescribing, chronic disease monitoring, rare disease management, and targeted therapy support.

Market Segmentation

By Disease Type

• Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
• Transthyretin-Mediated Amyloidosis Polyneuropathy (ATTR-PN/FAP)

By Payer Type

• Public / Government Insurance
• Private / Commercial Insurance
• Self-Pay / Out-Of-Pocket

By Patient Setting

• Inpatient Use
• Outpatient Use

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online / Specialty Pharmacies

Key Companies Analysed

• Pfizer
• BridgeBio Pharma
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• AstraZeneca
• Novartis
• Bayer
• Sanofi
• Johnson & Johnson
• Merck & Co
• AbbVie
• Bristol Myers Squibb
• Roche
• Amgen
• Takeda
• Novo Nordisk
• Astellas Pharma
• Alnylam
• Akcea Therapeutics
• Eidos Therapeutics

Geographic Coverage

• North America - Market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Sweden
  • Russia
  
  
• Asia-Pacific - Market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru
  
  

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

• Updated PDF report and an MS Excel workbook containing market tables and figures.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data.
• Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.